loading page

Comparison of the efficacy between immunochemotherapy and chemotherapy in patients with gastric cancer with synchronous liver metastasis: a real-world study
  • +8
  • Chao-Hui Zheng,
  • Guang-Tan Lin,
  • Zhi-Yu Liu,
  • Zhi-Xin Shang-Guan,
  • Jian-Xian Lin,
  • Ju Wu,
  • Gui-Rong Zeng,
  • Qi-Yue Chen,
  • Jian-Wei Xie,
  • Ping Li,
  • Chang-Ming Huang
Chao-Hui Zheng
Fujian Medical University Union Hospital

Corresponding Author:[email protected]

Author Profile
Guang-Tan Lin
Fujian Medical University Union Hospital
Author Profile
Zhi-Yu Liu
Fujian Medical University Union Hospital
Author Profile
Zhi-Xin Shang-Guan
Fujian Medical University Union Hospital
Author Profile
Jian-Xian Lin
Fujian Medical University Union Hospital
Author Profile
Ju Wu
Affiliated Zhongshan Hospital of Dalian University
Author Profile
Gui-Rong Zeng
Fujian Medical University Union Hospital
Author Profile
Qi-Yue Chen
Fujian Medical University Union Hospital
Author Profile
Jian-Wei Xie
Fujian Medical University Union Hospital
Author Profile
Ping Li
Fujian Medical University Union Hospital
Author Profile
Chang-Ming Huang
Fujian Medical University Union Hospital
Author Profile

Abstract

Background: Few studies have investigated the efficacy of comprehensive therapy, including immunotherapy, for gastric cancer with synchronous liver metastases (GCLM). We compared the effect between immunochemotherapy and chemotherapy alone as a conversion therapy on the oncological outcomes of patients with GCLM. Methods: Clinicopathological data of 100 patients with GCLM from February 2017 to October 2021 from our institution were retrospectively analyzed. The patients were divided into immunochemotherapy (n=33) and chemotherapy alone groups (n=67). Results: The baseline clinicopathological data did not significantly differ between two groups. The immunochemotherapy group had higher overall response (59.4% vs. 44.0%, P=0.029) and disease control rates (71.9% vs. 49.2%, P=0.036) than the chemotherapy group. The immunochemotherapy group showed better tumor regression in gastric mass, metastasis lymph nodes, and liver lesion than did the chemotherapy group. Ten (30.3%) patients in the immunochemotherapy group and thirteen (19.4%) in the chemotherapy group underwent surgery after conversion therapy. However, the difference was not significant. The overall survival (OS) and progression-free survival (PFS) rates were better in the immunochemotherapy group than in the chemotherapy group. Treatment-related adverse events occurred in 24 (72.7%) and 47 (70.1%) patients in the immunochemotherapy and chemotherapy groups, respectively. Conclusions: As a conversion therapy for GCLM, immunotherapy yielded better primary and metastatic tumor regression and survival benefit, with no increase in adverse events than did chemotherapy.